Salarius Shares Surge 37.8% Amid $6M Equity Offer and Decoy Merger

Introduction

SALARIUS PHARMACEUTICALS INC (NASDAQ: SLRX) is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. As of November 12, 2025, its shares are trading at $1.35, representing a 37.76% increase with a daily trading volume of 12,583,997 shares. The company focuses on correcting dysregulated gene expression in cancer cells through two platforms: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs).

Corporate Structure

Founded in 2011, Salarius operates from the Texas Medical Center Innovation facility. The company has between 11 and 50 employees, with David Arthur serving as CEO and Tess Burleson as COO. Bill McVicar, PhD, acts as Chair of the Board. Salarius has received a three-year $16.1 million award from the Cancer Prevention and Research Institute of Texas (CPRIT) and support from the National Pediatric Cancer Foundation.

Biopharmaceuticals by CDC

Developments and News

• November 10, 2025: Filed a Free Writing Prospectus under Rules 163/433 announcing a stock-for-stock merger with Decoy Therapeutics. Pro forma ownership will be approximately 85.2% for Decoy and 14.8% for Salarius, contingent on raising at least $6 million and meeting NASDAQ listing requirements. The company has secured $6.5 million in non-dilutive funding.
• November 12, 2025: Filed a Rule 424(b)(4) prospectus to offer 2,514,335 common shares and up to 9,333,332 warrants at $1.50 per share, aiming to raise a minimum of $6 million to fund the merger with Decoy.
• Ongoing clinical programs:
  • SP-2577 (seclidemstat): Currently in a Phase 1/2 trial for Ewing sarcoma, with combination studies alongside topotecan/cyclophosphamide and investigator-initiated trials with azacitidine for myelodysplastic syndromes and chronic myelomonocytic leukemia.
  • SP-3164: Conducting IND-enabling studies for a next-generation molecular glue targeting Ikaros and Aiolos, with clinical entry anticipated in the second half of 2023.

Financial and Strategic Analysis

Salarius' share price increase on November 12, 2025, reflects market response to its financing and merger plans. The 424(b)(4) offering at $1.50 per share aims to secure at least $6 million in proceeds. Key risks include limited liquidity for pre-funded and common warrants, maintaining NASDAQ compliance, and shareholder dilution from the merger. Management has indicated that proceeds will be used to support ongoing operations and the integration of Decoy’s programs, utilizing both dilutive and non-dilutive funding sources.

Market Position and Industry Context

Salarius operates in the oncology segment of pharmaceutical manufacturing, focusing on both solid tumors and hematologic cancers. Its lead asset, seclidemstat, has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration for Ewing sarcoma. Collaboration with MD Anderson Cancer Center supports its hematologic cancer trials. The dual-platform approach—TPIs and TPDs—positions Salarius among numerous companies addressing gene dysregulation through small molecules and molecular glues. The market for acute myeloid leukemia in the U.S. accounted for nearly 20,000 new cases in 2020, underscoring potential demand for innovative therapies.

tl;dr

On November 12, 2025, Salarius Pharmaceuticals’ stock rose 37.76% as the company filed a prospectus to raise at least $6 million through a common stock and warrant offering at $1.50 per share. This financing supports a pending merger with Decoy Therapeutics, which, upon completion, will result in Decoy shareholders holding approximately 85.2% of the combined entity. Conditions include securing minimum proceeds and meeting NASDAQ initial listing criteria. Clinical programs are ongoing, with SP-2577 in Phase 1/2 trials and SP-3164 advancing toward an anticipated clinical start in 2023, setting the stage for upcoming data and regulatory milestones.